{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzlnjp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzlnjp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/8\\\/18\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/8\\\/18\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/8\\\/18\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/8\\\/18\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EIn a single-site, retrospective study comparing the efficacy of several platinum doublet regimens in patients with EGFR wild-type, nonsquamous non\u2013small cell lung cancer, no differences were found in overall survival or response rate between platinum plus pemetrexed or nonpemetrexed therapies (eg, gemcitabine, taxanes).\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eretrospective study\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EEGFR wild-type\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Enonsquamous\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Enon\u2013small cell lung cancer\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eplatinum\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epemetrexed\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Egemcitabine\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etaxanes\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etargeted treatment\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eoncology clinical trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003EThis single-site, retrospective study compared the efficacy of platinum doublet regimens used as first-line chemotherapy for patients with EGFR wild-type, nonsquamous non\u2013small cell lung cancer (NSCLC). Investigators found no difference in survival, response rate, and prognostic factors. Eun Joo Kang, MD, Korea University Guro Hospital, Seoul, Korea, reported study results in a poster presentation [Kang EJ et al. \u003Cem\u003EAnn Oncol\u003C\/em\u003E. 2015].\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EMolecular research and targeted agents like gefitinib and erlotinib have improved outcomes for a subset of NSCLC patients with EGFR mutations. Yet, platinum doublet regimens remain first-line therapy for patients with EGFR wild-type NSCLC, which accounts for more than half of all NSCLC cases. In a randomized phase 3 study, overall survival (OS) was significantly better with pemetrexed\u2005+\u2005cisplatin than a nonpemetrexed therapy (gemcitabine\u2005+\u2005cisplatin) in a Western population composed of chemotherapy-na\u00efve patients with adenocarcinoma (12.6 vs 10.9 months; \u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.03) [Scagliotti GV et al. \u003Cem\u003EJ Clin Oncol\u003C\/em\u003E. 2008].\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EDr Kang and colleagues conducted a retrospective analysis on 165 patients with EGFR wild-type nonsquamous NSCLC who had received first-line treatment with pemetrexed\u2005+\u2005platinum (PP) or nonpemetrexed + platinum (NPP) chemotherapy at Korea University Guro Hospital between 2007 and 2013, analyzing progression-free survival (PFS), OS, response rate, and prognostic factors.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EAlmost all patients (91.5%) had adenocarcinoma. Average age was 66 years and 71.5% were men. At diagnosis, 80.6% had stage IV disease. During treatment, 43% had received PP and 57% had received NPP. In the NPP group, patients had mainly received gemcitabine + carboplatin (37.2% of all NPP patients), paclitaxel + carboplatin (19.1%), gemcitabine + cisplatin (18.1%), docetaxel + cisplatin (11.8%), or paclitaxel\u2005+\u2005cisplatin (7.4%). Patient characteristics were similar in the PP and NPP groups.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003ENo difference between the 2 groups was reported in median PFS (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.12) or OS (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.42), nor did OS differ depending on which specific regimen was used (\u003Cem\u003EP\u2005=\u2005\u003C\/em\u003E.82). For patients who had received PP, median PFS and OS were 4.6 months (95% CI, 3.8 to 5.4) and 18.7 months (95% CI, 11.7 to 25.8), respectively. For patients who had received NPP, median PFS and OS were 6.2 months (95% CI, 3.4 to 5.0) and 12.2 months (95% CI, 10.3 to 14.1), respectively. There were no significant differences in response rate, which was 26.8% in the PP group and 28.7% in the NPP group (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.78).\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EDuring multivariate analysis looking at prognostic factors, prolonged OS was associated with a few subgroups:\u003C\/p\u003E\n         \u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\n               \u003Cp\u003EIn PP patients:\n\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-2\u0022\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\n                        \u003Cp id=\u0022p-9\u0022\u003EStages I\u2013III at diagnosis\u003C\/p\u003E\n                     \u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\n                        \u003Cp id=\u0022p-10\u0022\u003EMetastasis restricted to lung, pleura, or both\u003C\/p\u003E\n                     \u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\n                        \u003Cp id=\u0022p-11\u0022\u003ETreatment\u2005\u003Cspan class=\u0022underline\u0022\u003E\u0026gt;\u003C\/span\u003E\u20052nd-line chemotherapy vs 1st-line only\u003C\/p\u003E\n                     \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n               \u003C\/p\u003E\n            \u003C\/li\u003E\u003C\/ul\u003E\n         \u003Cul class=\u0022list-unord \u0022 id=\u0022list-3\u0022\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\n               \u003Cp\u003EIn NPP patients:\n\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-4\u0022\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\n                        \u003Cp id=\u0022p-13\u0022\u003EMetastasis restricted to lung, pleura, or both\u003C\/p\u003E\n                     \u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\n                        \u003Cp id=\u0022p-14\u0022\u003ETreatment\u2005\u003Cspan class=\u0022underline\u0022\u003E\u0026gt;\u003C\/span\u003E\u20052nd-line chemotherapy vs 1st-line only\u003C\/p\u003E\n                     \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n               \u003C\/p\u003E\n            \u003C\/li\u003E\u003C\/ul\u003E\n         \u003Cp id=\u0022p-15\u0022\u003EThe data suggest no clear advantage in PFS, OS, or response rate for patients with wild-type EGFR, nonsquamous NSCLC given PP or NPP as first-line therapy. Although pemetrexed plus platinum has been regarded as superior in nonsquamous NSCLC, this study did not support that belief. Because the study was retrospective, relatively small-scale, and conducted only on patients from 1 hospital, further confirmation is needed.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/8\/18.1.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzlnjp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}